• OPEN AN ACCOUNT
A+| A| A-|
Indian Indices
Sensex
76,802.90 -607.08
( -0.78%)
Global Indices
Nasdaq
51,584.84 71.29
(0.14%)
Dow Jones
7,519.91 78.81
(1.06%)
Hang Seng
70,971.12 -82.37
(-0.12%)
Nikkei 225
10,394.87 -113.74
(-1.08%)
Forex
USD-INR
94.51 -0.04
(-0.04%)
EUR-INR
109.43 -0.23
(-0.21%)
GBP-INR
126.51 -0.33
(-0.26%)
JPY-INR
0.59 0.00
(-0.05%)

EQUITY - MARKET SCREENER

DCM Shriram Industries Ltd
Industry :  Sugar
BSE Code
ISIN Demat
Book Value()
523369
INE843D01027
28.6026726
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
DCMSRIND
12.13
505.48
EPS(TTM)
Face Value()
Div & Yield %
3.19
2
0.69
 

string metaverse ltd
MPS jumps on acquiring US-based Unbound Medicine
Feb 01,2026
The acquisition will be executed through MPS North America LLC, a wholly owned subsidiary of MPS. The transaction is expected to be completed on or before 10 February 2026, subject to the fulfilment of customary closing conditions, the company said in a regulatory filing.

The acquisition will be carried out for a cash consideration of $16.50 million, subject to customary adjustments.

Founded in 1999, Unbound Medicine provides digital medical reference tools, clinical decision-support solutions and healthcare learning platforms. Its services are delivered through proprietary mobile and web-based platforms and follow a subscription-led institutional business model. The company serves medical schools, hospital systems and healthcare associations across the United States and Canada.

MPS said the acquisition aligns with its strategy of building platform-led, recurring-revenue businesses. The transaction is expected to support revenue diversification, enable cross-selling opportunities and strengthen the company’s presence in the North American market.

MPS provides learning and platform solutions combining content, technology and artificial intelligence. The company is focused on scaling operations and strengthening its position in the global learning and knowledge services market.

On a consolidated basis, net profit of MPS rose 57.32% to Rs 55.44 crore while net sales rose 9.42% to Rs 194.44 crore in Q2 September 2025 over Q2 September 2024.